To understand the prognostic implication of this alteration, we analyzed the outcomes of a subset (n = 438) of patients from the FOCUS trial in whom the S:CORT consortium had analyzed a wider panel of CRC genes including KRAS, NRAS, BRAF, MSI, and TP53. Here, TP53 is linked to colorectal carcinoma.